

Cover Story
By Claire Dietz and Matthew Bin Han Ong
The Cancer Prevention and Research Institute of Texas—the second largest publicly-funded granting organization for cancer after NIH—may receive $3 billion more to stay open past its current sunset date in 2023.
Conversation with The Cancer Letter
By Claire Dietz and Matthew Bin Han Ong
In Brief
Funding Opportunities
Clinical Roundup


Drugs & Targets
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”
- Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)
- One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- As more people are surviving cancer, we must continue funding bold science
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis















